Market Signal Briefing

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in KBR, Inc. ("KBR, Inc." or the "Company") (NYSE: KBR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of KBR, Inc. investors who were adversely affected by alleged securities fraud between May 6, 2025 and June 19, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/kbr-inc-lawsuit-submission-form?prid=170641&wire=3

KBR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) despite the knowledge that the U.S. Department of Defense’s Transportation Command, for months, had material concerns with HomeSafe’s ability to fulfill the global household goods contract, defendants claimed that the partnership was without issue, and would ramp up in future quarters; and (2) as a result, defendants’ statements about KBR’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT'S NEXT? If you suffered a loss in KBR, Inc. during the relevant time frame, you have until November 18, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Unicycive Therapeutics, Inc. investors who were adversely affected by alleged securities fraud between March 29, 2024 and June 27, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/unicycive-therapeutics-inc-lawsuit-submission-form?prid=170643&wire=3

UNCY investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Unicycive’s readiness and ability to satisfy the FDA’s manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application’s regulatory prospects were likewise overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Unicycive Therapeutics, Inc. during the relevant time frame, you have until October 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fluor Corporation ("Fluor Corporation" or the "Company") (NYSE: FLR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fluor Corporation investors who were adversely affected by alleged securities fraud between February 18, 2025 and July 31, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/fluor-corporation-lawsuit-submission-form?prid=170645&wire=3

FLR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) costs associated with the Company’s infrastructure projects; Gordie Howe, I-635/LBJ, and I-35 were growing because of, inter alia, subcontractor design errors, price increases, and scheduling delays; (ii) the foregoing, as well as customer reduction in capital spending and client hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company’s business and financial results; (iii) accordingly, Fluor’s financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company’s risk mitigation strategy was overstated, and the impact of economic uncertainty on the Company’s business and financial results was understated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Fluor Corporation during the relevant time frame, you have until November 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Dow Inc. ("Dow Inc." or the "Company") (NYSE: DOW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Dow Inc. investors who were adversely affected by alleged securities fraud between January 30, 2025 and July 23, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/dow-inc-lawsuit-submission-form?prid=170644&wire=3

DOW investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Dow’s ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (ii) the true scope and severity of the foregoing headwinds’ negative impacts on Dow’s business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales and demand for the Company’s products, and an oversupply of products in the Company’s global markets; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Dow Inc. during the relevant time frame, you have until October 28, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortinet, Inc. ("Fortinet, Inc." or the "Company") (NASDAQ: FTNT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortinet, Inc. investors who were adversely affected by alleged securities fraud between November 8, 2024 and August 6, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/fortinet-inc-lawsuit-submission-form?prid=170648&wire=3

FTNT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that defendants knew that the refresh cycle would never be as lucrative as they represented, nor could it, because it consisted of old products that were a “small percentage” of the Company’s business. Moreover, defendants misrepresented and concealed that they did not have a clear picture of the true number of FortiGate firewalls that could be upgraded. And while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that it had aggressively pushed through roughly half of the refresh in a period of months, by the end of 2Q 2025.

WHAT'S NEXT? If you suffered a loss in Fortinet, Inc. during the relevant time frame, you have until November 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- A new class-action lawsuit is targeting KBR, Inc. (NYSE: KBR), alleging the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract. The suit, Norrman v. KBR, Inc., et al., No. 4:25-cv-04464 (S.D. Tex.), was filed after the company’s stock plunged following the termination of a multi-billion-dollar deal.

National shareholders rights firm Hagens Berman urges KBR investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Class Period: May 6, 2025 – June 19, 2025
Lead Plaintiff Deadline: Nov. 18, 2025
Visit: www.hbsslaw.com/investor-fraud/kbr
Contact the Firm Now: [email protected]
                                        844-916-0895

KBR, Inc. (KBR) Securities Class Action:

The legal action seeks to represent shareholders who purchased KBR securities between May 6, 2025, and June 19, 2025. It claims that KBR executives provided a falsely optimistic outlook on a crucial partnership just as it was on the verge of collapse.

The litigation stems from the Department of Defense U.S. Transportation Command (TRANSCOM) canceling its global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR. The decision, announced on June 20, 2025, caused KBR shares to fall over 7% as investors reacted to the loss of a contract valued at up to $20 billion over a potential nine-year term.

The suit highlights a key discrepancy: on May 6, 2025, during its Q1 earnings call, KBR assured investors that the HomeSafe partnership was "strong" and "excellent" and that the company was "very confident in the future of this program."

However, just weeks later, on June 19, 2025, HomeSafe disclosed that TRANSCOM had terminated the contract for cause. The termination reportedly came after months of operational issues, including chronic delays, missed pickups, and a rise in complaints about damaged goods. The complaint alleges that KBR was aware of TRANSCOM’s material concerns but chose to conceal them from investors. The lawsuit argues that this misrepresentation led to the significant financial losses suffered by shareholders.

“We’re focused on whether KBR may have intentionally misled investors about the true status of the relationship with TRANSCOM and the contract,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in KBR and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the KBR case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding KBR should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

Ethereum (CRYPTO: ETH) and BitMine Immersion Technologies Inc. (NYSE:BMNR) are moving in lockstep, with ETH reclaiming $4,700 and BitMine stock rising more than 9% on the back of its massive $13.4 billion crypto treasury.

Ethereum Price Breakout Clears $4,600 With $5,000 Now In Sight

ETH Key Technical Levels (Source: TradingView)

Ethereum has broken above the triangle structure that capped price since August, with buyers lifting the token through $4,600 resistance. 

Trading volume and on-balance flows confirm renewed inflows, while moving averages stacked above $4,300 provide a strong base.

The breakout puts $5,000 back in focus, with potential extension toward $5,200 if momentum continues. 

Analysts note that defending $4,500–$4,600 is essential for sustaining the move.

BitMine Stock Jumps On ETH Bet

BMNR Technical Analysis (Source: TradingView)

BitMine Immersion, the largest corporate Ethereum holder, advanced more than 9% to trade above $62, breaking through its descending trendline and testing the top of a cup-and-handle structure.

The company disclosed holdings of 2.83 million ETH worth $12.8 billion as reported on Oct. 5, alongside $456 million in cash and $113 million in equity stakes. 

Its balance sheet exposure makes BMNR a direct proxy for Ethereum's price.

Treasury Scale And Market ImpactBitMine ranks as the world's largest Ethereum treasury and the second-largest crypto treasury overall, behind Strategy Inc. (NASDAQ:MSTR). 

Chairman Thomas "Tom" Lee said the company's goal is to reach ownership of 5% of total ETH supply, calling it part of the "two supercycle narratives" of artificial intelligence and cryptocurrency.

Lee told investors that Ethereum's role as the base layer for Wall Street adoption and blockchain AI integration will be "one of the biggest macro trades over the next 10 to 15 years."

Why It MattersThe rise of BitMine as Ethereum's largest corporate holder marks a turning point in how equity markets price crypto exposure.

Unlike Bitcoin, where ETFs dominate headlines, Ethereum's corporate treasuries are quietly shaping a parallel playbook.

BitMine's ambition to own 5% of ETH supply would make it larger than most sovereign reserves and rival traditional commodity stockpiles.

The company's dual framing of Ethereum as both financial plumbing for Wall Street and infrastructure for AI creates a rare macro crossover.

This positions ETH not just as a cryptocurrency, but as the backbone of two of the century's biggest investment themes.

If ETH sustains above $4,600, BMNR's chart projects a retest of $70 and potentially a move toward $130, tying equity upside directly to Ethereum's trajectory.

Read Next:

HSDT Follows Michael Saylor’s Playbook With $530M Solana Bet—Is This The Next MSTR?
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

In brief
Zcash is being highlighted by notable individuals on social media.
The token’s price has increased nearly 240% over the past two days.
Mert Mumtaz said Zcash would hit $1,000.
Zcash’s price rose to $165 on Monday as Mert Mumtaz, CEO of Solana infrastructure firm Helius Labs, continued cheerleading the token on X, among other notable crypto observers.

Mumtaz has emerged one of Zcash’s most vocal backers, and he said on Monday that he “love[s] shilling privacy stuff because it actually ends up making a difference in the privacy properties of these systems.” He called for the token to hit $1,000.

gorgeous chart

The amount of ZEC being shielded on Zcash is going up and to the right over time

I love shilling privacy stuff because it actually ends up making a difference in the privacy properties of these systems (see the rightmost vertical bump)

$1,000 pic.twitter.com/E3Y5NclR4A

— mert | helius.dev (@0xMert_) October 6, 2025

Alongside his price prediction, Mumtaz posted a chart displaying the amount of Zcash being “shielded” through zero-knowledge proofs. He noted that the amount of funds effectively being masked “is going up and to the right over time.”

Zcash changed hands around $162 on Monday, a 7.5% increase over the past day, according to crypto data provider CoinGecko. The cryptocurrency’s price has surged nearly 240% over the past two weeks, but it remains far off all-time highs.

Zcash debuted in 2016, and its price peaked around $3,200 then. On Monday, Zcash was changing hands around its highest level since April 2022.

When asked about his interest in Zcash, Mumtaz directed Decrypt to a post on X, in which he says he likes Zcash because it has “a stronger privacy and scale design” than alternatives like Monero, fresh talent entering its ecosystem, and a longstanding community.

“Do not allocate what you're not willing to lose, this is risky,” he said in the post. “Only look into it if you agree with the argument on its merits.”

Mumtaz acknowledged to Decrypt that other people’s social media activity “also likely helped start an interest flywheel.”

A crypto streamer who goes by Gainzy on X shared a link to a livestream on Monday alongside an image of Zcash's logo. Chris Burniske, a partner at venture capital firm Placeholder, meanwhile shared a link to the company’s thesis on Zcash on X, which also mentions Bitcoin. 

“While Zcash was in part inspired by Bitcoin, the community has never been content being ‘Bitcoin but with privacy,’” it states. “Instead, they have recognized other core deficiencies in Bitcoin’s design, and worked to create a more sustainable system.”

A notable venture capitalist called Naval Ravikant also highlighted Zcash on X last week. The post has been viewed 2.9 million times. He called Zcash “insurance against Bitcoin,” suggesting that it has beneficial properties compared to the asset often portrayed as digital gold.

Zcash is used for private transactions, but users can also send transparent ones. Bitcoin transactions are recorded on a public ledger that anyone can see, so they are comparatively pseudonymous because wallet addresses aren’t tied to actual identities.  

Last week, crypto data provider Messari said that Zcash was leading “weekly mindshare with a 1,000% increase” on X. That means that interest had risen notably in the token on social media, and more so than other cryptocurrencies like Litecoin and Curve.

Zcash’s recent rally follows news from crypto asset manager Grayscale, which at the beginning of this month, said on X that it was creating a private placement for Zcash, allowing eligible investors to gain exposure to the token.

When it comes to renewed interest in Zcash, Gainzy doubted that it had anything to do with its technical merits while streaming on Monday.

"Retail doesn't care about zero-knowledge proofs. They don't care about retail about shielded transactions," he said. "They care about green candles, bro. They care about dollar signs going up, and that's finally happening."

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Ethereum (ETH) is showing strong bullish momentum as technical indicators suggest the cryptocurrency could climb toward $5,200 in the next 4-6 weeks. Trading at $4,532, ETH remains above key support levels, providing a solid base for further upside despite short-term consolidation.

Institutional adoption surges as treasuries turn to digital assets in uncertain political times.

Key Takeaways

Bitcoin has reached a new all-time high above $126,000, driven by sustained institutional accumulation.
Institutional investors and corporate treasuries increasingly treat Bitcoin as a store of value, not just a speculative asset.

Bitcoin reached a new all-time high above $126,000 today, solidifying the digital asset’s status as a preferred store of value amid global political instability.

The milestone reflects sustained institutional accumulation, with corporate treasuries continuing to integrate Bitcoin into their investment strategies throughout 2025.

Sovereign funds have shown renewed interest in the digital asset as global political tensions reinforce Bitcoin’s positioning as a hedge similar to gold.

The rally underscores Bitcoin’s evolution from speculative trading vehicle to institutional store of value, with treasuries showing no signs of slowing their accumulation strategies.

Disclaimer

Key Takeaways
How have whales influenced Ethereum’s latest move?
Whales injected over $72M into ETH, reinforcing confidence as prices held above $4,460 and trendline support.

What metrics define Ethereum’s next major breakout?
A break above $4,770 could confirm continuation, backed by a rising Stock-to-Flow ratio and bullish trader positioning.

Ethereum [ETH] whales have intensified their accumulation pace, with on-chain data showing over $72 million in combined inflows across trading platforms. 

A whale deposited $33 million in USD Coin [USDC] on Hyperliquid [HYPE] to purchase 7,311 ETH, while another withdrew 8,695 ETH worth $39.5 million from Binance. 

These transactions underscore strong institutional conviction and continued confidence in Ethereum’s resilience above key technical zones. 

Moreover, this aggressive accumulation amid market stability reveals a strategic buildup ahead of potential upward continuation.

It reinforces the growing narrative of long-term investor dominance across the Ethereum market landscape.

Bulls protect the $4,460 support zone
Ethereum’s daily chart reflected a solid uptrend, supported by the ascending trendline connecting higher lows from early July.

The price has remained comfortably above the $4,460 support level, while targeting the next key resistance around $4,770. 

This pattern shows bullish control, with each dip attracting strong demand near the trendline.

Meanwhile, the DMI indicator confirmed this momentum — +DI at 27.86 dominated -DI at 20.51, and the ADX hovering around 20 suggested that the trend was gaining strength. 

Therefore, sustained closes above $4,460 could propel Ethereum toward a new breakout phase above $4,770.

Source: TradingView

Tightening Ethereum supply dynamics
Ethereum’s Stock-to-Flow ratio has surged to 47.16, highlighting a sharp contraction in available supply relative to issuance. 

This rise signals that fewer coins are circulating while demand continues to climb, often preceding mid-term price expansions. 

The ongoing deflationary effect since the Merge has reinforced Ethereum’s scarcity narrative, enhancing its appeal among institutional holders. 

This increase in the Stock-to-Flow metric aligns with heightened accumulation from large wallets, suggesting that supply compression may further amplify Ethereum’s upside potential as the broader market stabilizes.

Traders align with Ethereum’s bullish momentum
60.52% of traders held long positions compared to 39.48% shorts at press time, pushing the Long/Short Ratio to 1.53. This bullish tilt indicates that market participants are positioning for further upside. 

It also reflects growing confidence in Ethereum’s ability to sustain strength above the $4,460 support and potentially challenge $4,770 resistance. However, short-term corrections remain possible if leverage rises excessively. 

Still, this alignment between retail traders and whale behavior adds confluence to Ethereum’s ongoing rally, showing sentiment and price structure moving in the same direction.

Could whale conviction fuel Ethereum’s next major rally?
Ethereum’s price action, supported by whale inflows, rising Stock-to-Flow ratio, and bullish derivatives data, suggests momentum remains intact. 

The defense of $4,460 as a key structural level highlights buyers’ dominance, while the next test at $4,770 could confirm a renewed breakout phase.

These overlapping metrics demonstrate a synchronized buildup of on-chain and market confidence. 

If whale activity continues reinforcing liquidity and demand, Ethereum may be gearing up for a sustained advance — potentially marking the beginning of its next macro expansion cycle.

21h05 ▪
5
min read ▪ by
Mikaia A.

Summarize this article with:

After setting a new historic record by nearing 125,000 dollars, Bitcoin shows signs of fatigue. Is it ready to climb another step or will it consolidate under resistance? Crypto analysts do not share the same enthusiasm. While some anticipate a rise towards 150,000 dollars, others predict an accumulation phase. The recent ATH has rekindled hope, but caution remains necessary.

In brief

Bitcoin surpassed 124,000 dollars, fueling speculation of a new increase.
Traders see consolidation between 118,000 and 123,000 dollars as a probable scenario.
An AI model from CryptoQuant anticipates a calm October, with no significant breakout expected.

Bitcoin at $124,000: Between chartist excitement and trader caution
At first glance, Bitcoin seems in excellent shape. But beyond the peak, the technical reality reminds us that the crypto star remains locked within a well-defined channel. Since its jump above 125,000 dollars, BTC is moving between a support identified around $108,000 and resistance at $123,000. This range acts as a real psychological and technical barrier.

Some traders mention a classic “weekend squeeze” followed by a retracement. According to Daan Crypto Trades, this bullish move quickly gave way to a pause, suggesting a perpetual rather than fundamental impulse. Another analyst believes the rise was “entirely driven by perpetual contracts” (TedPillows, X), making the progress fragile without institutional support.

For others, the current setup corresponds to a recharging phase. An informed user points out that a return to the 50 exponential moving average in H4 — located at $119,250 — would be healthy before another breakout attempt. “I therefore still favor long positions over shorts from this moving average“, CrypNuevo specifies.

Bitcoin must prove that this $124,000 resistance is weakening. And any more moderate pullback or correction from now on would go in this direction.

Rekt Capital, X.
Crypto and institutions: the growing influence of ETFs on Bitcoin price
Beyond graphical analysis, another key factor is mentioned by crypto analysts: the impact of institutional flows. According to Ryan Lee, Chief Analyst at Bitget, the recent rise of BTC is based on much more solid foundations than mere transient enthusiasm. 

In his view, massive flows into spot ETFs contributed to driving the price upward.

Indeed, data confirms unprecedented enthusiasm from asset managers. The correlation between peaks of crypto ETF inflows and price accelerations is well established. Furthermore, some analysts believe that if this momentum persists, the next step could be a test of the 130,000-dollar area. This positions BTC as a strategic asset in institutional portfolios.

Even Ethereum benefits indirectly: a rebound towards $4,800 to $5,000 is envisaged if the momentum holds. In this context, savvy crypto investors bet on diversified exposure. The evolution of spot ETFs is therefore to be monitored as a major barometer of overall confidence in the crypto industry.

When AI cools enthusiasm: the limits of an “Uptober” 2025
But in this chorus of optimism, one algorithmic voice tempers the euphoria. CryptoQuant, via its AI tool NBeats Ensemble, estimates that a true breakout in October remains unlikely. According to this model trained on 379 on-chain variables, the probability of a decisive break is low.

The analysis mentions prolonged consolidation, with expected fluctuations in the upper half of the range, between $118,000 and $123,000. This situation resembles a phase of “silent re-accumulation” orchestrated by large holders.

The model forecasts continuous fluctuations inside the current range. However, there is a subtle but important nuance in this forecast: the model expects these fluctuations to occur mainly in the upper half of this range.

CryptoQuant 
This scenario supports the idea of a market in transition rather than explosion. Indeed, many analysts note that the absence of clear macro catalysts, such as a Fed decision postponed due to shutdown, slows momentum.

Key figures and points to remember:

The BTC price reached $125,700 over the weekend before retreating to $124,000;
The major support lies between $117,000 and $118,000;
The CryptoQuant AI model excludes a breakout before several weeks;
The overall sentiment remains at moderate “greed” with 71/100;
ETFs attracted more than $3.2 billion in a few days.

Despite doubts about a booming “Uptober,” the overall momentum remains bullish. Many analysts believe that bitcoin has not yet shown its full potential. For them, the end of 2025 could mark a historic turning point, with a surge few would have dared to anticipate months earlier.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Mikaia A.

La révolution blockchain et crypto est en marche ! Et le jour où les impacts se feront ressentir sur l’économie la plus vulnérable de ce Monde, contre toute espérance, je dirai que j’y étais pour quelque chose

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.

0xngmi noted integrity demanded action, as Aster’s API inflated overall metrics and couldn’t be corrected with a warning.

DeFiLlama has officially delisted perpetual futures volume data from Aster.

The decision follows concerns over suspicious trading activity that mirrors that of Binance.

DeFiLlama Moves to Delist Aster (ASTER)
0xngmi, DeFiLlama’s pseudonymous co-founder, shared via X that there has been an ongoing investigation into the BNB-based decentralized exchange’s volumes. He compared XRPUSD and ETHUSDT trading on Aster with its competitor Hyperliquid. The results showed that the former’s pairs had an almost 1:1 match with Binance’s perpetual futures volumes, while its counterpart showed some differences.

The analytics platform explained that it also couldn’t check detailed order data, such as market maker or filler addresses, which made it hard to know if the trades were real or manipulated. This resulted in the decision to remove Aster’s perpetual data from the DeFiLlama dashboard.

Aster, which launched in September, quickly rose as a strong competitor to Hyperliquid. By late September, its daily perpetual trading volume had surged to $60 billion, briefly surpassing that of its rival.

The perpetuals DEX exchange’s dominance was supported by CZ’s public endorsement and backing from YZi Labs, which holds a minority stake through its earlier investment in Astherus.

0xngmi’s Response to Community Backlash
Elsewhere, the delisting has gotten mixed reactions from the X crypto community. Some users backed DeFiLlama’s move, viewing it as a step toward protecting data integrity, while others criticized it for alleged bias and spreading unnecessary FUD.

You may also like:

Bitcoin (BTC) Pushes Past $112K, Hyperliquid (HYPE) Soars by 7% Daily: Market Watch

Is MrBeast Bullish on ASTER? $1.28M Wallet Starts Speculation

HYPE Price Climbs Higher with $84B Volume and NFT Frenzy

0xngmi has since denied conflict of interest claims, clarifying that they have never held HYPE or ASTER tokens nor opened any trading positions involving them. Additionally, he dispelled the allegations of unfairness by stating that similar actions had been taken against other exchanges.

In an update, he emphasized that the platform’s credibility depends on providing reliable figures since users make investment choices based on its data. He also dismissed accusations that the delisting was paid for, explaining that the development followed an unusual spike in trading volumes that prompted a review.

“All we care is about the integrity of our data cause its important that users can trust it,” read the statement.

0xngmi added that the move was made openly because a past quiet delisting of Aster had led to rumors of secret deals. The statement concluded with him sharing that a warning was also not possible since the platform’s API would still distort the overall data.

Tags:

Bitcoin on Monday recorded a fresh all-time high just above $126,000 as cryptocurrencies continue their uptrend in the first week of October.

CryptocurrencyTickerPriceBitcoin(CRYPTO: BTC)$125,568Ethereum(CRYPTO: ETH)$4,699Solana(CRYPTO: SOL)$235.75XRP(CRYPTO: XRP)$3.04Dogecoin(CRYPTO: DOGE)$0.2692Shiba Inu(CRYPTO: SHIB)$0.00001296Notable Statistics:

Coinglass data shows 147,328 traders were liquidated in the past 24 hours for $304.31 million.       
In the past 24 hours, the top gainers include Starknet (CRYPTO: STRK), PancakeSwap (CRYPTO: CAKE) and Mantle (CRYPTO: MNT).
Notable Developments:

Grayscale Launches Wall Street’s First Ethereum, Solana Staking ETFs
ChatGPT Says Solana’s $240 Test Could Decide Its Entire Bull Run
Bitcoin Targets $130,000—And This ‘Supertrend’ Indicator Just Flipped Bullish
Bitcoin’s $125,000 All-Time High Proves This Pattern You Should Keep Watching, Analyst Says
Strategy Rewrites Corporate Playbook With $3.9B Bitcoin Gain—MSTR To Break Out?
Anthony Pompliano Says Stocks Are Not ‘Productive Enough’ If They Get Beaten By Bitcoin And Gold: BTC Is The ‘Hurdle Rate’
Trader Notes: Crypto trader Kaleo noted that historically, October is Bitcoin's second most bullish month with an average gain of 15.33%, while November tops all months with an average surge of 40.33%.

The current BTC rally is still in its early stages.

Rekt Capital observed that Bitcoin's Price Discovery Correction 2 has ended. While shallower than previous cycles, its duration mirrored 2017 and 2021. BTC is now positioned to enter Price Discovery Uptrend.

Traderview2 highlighted that each upward move in the ongoing grind has triggered clusters of short liquidations.

The perpetuals market remains bearish and unable to sustain the rally, whereas spot buying has been the main driver. Continued spot demand could force more shorts to cover, adding upward momentum.

Ted Pillows pointed out that Bitcoin has surged nearly 10% since the U.S. government shutdown, demonstrating that major negative events can sometimes spark strong bullish moves.

Read Next:

Here’s Why Paul Tudor Jones Just Called Bitcoin ‘Very Very Appealing’
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

The US SEC recently approved a new set of generic listing standards in September 2025 for commodity-based exchange-traded products, including those tied to digital assets. 

Many in the industry now believe that this regulatory move could hasten the listing of spot ETFs for altcoins such as XRP, possibly as early as October. As it stands, all fingers point to Spot XRP ETFs hitting the industry at the end of October.

New SEC Guidelines To Speed Up Spot XRP ETF Approval
The prospect of Spot XRP ETFs launching in October is very promising. However, this anticipation now faces uncertainty due to a US federal government shutdown that has paralyzed much of the SEC’s routine operations.

Just weeks before the shutdown, the SEC introduced a new set of generic listing standards for commodity-based exchange-traded products. Under the old framework, each new ETF required a case-by-case review under Section 19(b), alongside an S-1 filing, often resulting in months of regulatory delay. This delay can be seen among Spot XRP ETF applications, many of which have been filed between January and March 2025 but are still waiting for approval.

The new rules, however, allow exchanges such as Nasdaq, NYSE Arca, and Cboe to list qualifying ETFs automatically if they meet predefined standards. This change prompted the SEC to ask multiple issuers, including those behind XRP, Solana, and Cardano ETFs, to withdraw and refile their earlier applications under the new system.

Kenny Nguyen, a well-known crypto commentator, shared his view on X, noting that all eleven XRP ETF filings have already crossed their generic listing standards deadlines from their application date and are ready for simultaneous approval. ETF reviews can be completed in as little as 75 days under the new framework, meaning the filings have already surpassed that window. However, the SEC’s new generic listing standards officially took effect on October 1, the very same day the US government slipped into a partial shutdown.

Speaking of shutdowns, the US government entered a partial shutdown on October 1 after lawmakers failed to pass a new spending bill, which has left many federal agencies without operating funds. The SEC, which oversees ETF approvals, is among the agencies most affected.

This shutdown has paused the review and approval process for all pending spot ETF applications, including those tied to the altcoin. Financial law firm McGuireWoods noted that filings can still be made, but most reviews, responses, and actions are suspended. 

The Funds To Launch Once The Government Reopens
The timing of Spot XRP ETFs now depends on the US Congress ending the ongoing shutdown. Therefore, the crypto market could witness a quick wave of ETF approvals all at once once the SEC is back online. 

The SEC’s generic listing standards mean all that’s required is an S-1 registration (disclosure of fund structure, risks, etc.). As such, Spot XRP ETFs could hit the market in October, since their deadlines under the new rules have been extended. Even using the old timeline, all current XRP ETF applications would surpass the 120-day deadline between October 18 and 25.

XRP trading at $2.98 on the 1D chart | Source: XRPUSDT on Tradingview.com
Featured image from Adobe Stock, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

As Bitcoin continues to climb major milestones, breaking a new all-time high (ATH) at $125,388 on October 5th, industry experts are increasingly making bullish predictions for the leading cryptocurrency. 

Amid growing confidence surrounding the asset, Bitwise CIO Matt Hougan has made a bold prediction for Bitcoin-based investment products.

On October 6th, Hougan expressed confidence in the sustained institutional demand for Bitcoin, suggesting that the total assets under management (AUM) held by Bitcoin funds worldwide could eventually surge to $1 trillion.

HOT Stories

Bitcoin funds achieve $200 Billion milestoneWhile Hougan’s prediction has sparked widespread discussion across the crypto community, it follows a major development: global Bitcoin funds have surpassed $200 billion in total assets under management.

The milestone, shared by the Bitwise Managing Director, highlights the accelerating demand for Bitcoin among institutional investors.

In less than two years since their launch, global Bitcoin AUMs have more than quadrupled since early 2024. During this period, Bitcoin has recorded a remarkable price growth of over 100% in the past year, gaining significant traction among both retail and institutional investors.

The rapid increase in Bitcoin fund AUM is largely driven by record spot BTC ETF inflows, renewed market optimism, and the growing adoption of Bitcoin as a strategic reserve asset.

Bitcoin hits new ATH at $125,388On Sunday, October 5th, Bitcoin reached a record-breaking high of $125,388, as the broader crypto market experienced a sharp resurgence amid the strong “Uptober” rally.

The milestone has reignited interest among skeptics while further boosting investor confidence. However, analysts have warned of a possible short-term price correction, which could temporarily slow momentum.

Still, many market watchers believe Bitcoin could maintain its uptrend and set new highs if it manages to hold above the $124,000 level on the weekly chart.

With this new ATH achieved at the very start of the “Uptober” bull run, several analysts are predicting the possibility of Bitcoin reaching $150,000 before the end of the year.

Key takeaways:

Paul Tudor Jones expects massive upside from US markets, but notes that widespread retail and institutional participation is required for a market peak.

US stock market valuations and economic conditions don’t point to an immediate downturn, supporting the thesis of continued speculative momentum.

Billionaire investor Paul Tudor Jones firmly believes that US financial markets are far from a bubble and points to the US government’s growing fiscal crisis as a catalyst for risk-on assets, including Bitcoin (BTC). Tudor’s main thesis relies on loose monetary policies, retail flows and speculation.

US fiscal debt issue favors allocation in risk-on assets, including BitcoinIn July, US President Donald Trump signed the “One Big Beautiful Bill,” which extended tax cuts and raised the debt ceiling, creating a $2.1 trillion deficit impact by 2029, according to The Congressional Budget Office. 

US government debt, USD (left, red) vs. Bitcoin/USD (blue). Source: TradingView / CointelegraphThe interest in the US debt is projected to exceed $1 trillion in 12 months for the first time in history, causing analysts to expect a 127% debt-to-GDP ratio for 2026. Such fiscal stress raises doubts about confidence in the US's ability to repay its debt as investors worry that the government will need to inflate, or otherwise devalue the currency. 

Those concerns intensify as 33% of US Treasurys are held by foreign entities. Injecting liquidity and suppressing real yields tend to drive those holders to seek better return opportunities elsewhere, putting downward pressure on demand for Treasurys and on the dollar itself.

Yields on 10-year Treasury (left) vs. US Dollar Index (DXY, right). Source: TradingView / CointelegraphTudor Jones draws similarities with the 1999 period, which marked Nasdaq’s 90% gains in five months that culminated with the “dot-com crash” in 2000. But this time around, conditions are far more favorable. For starters, the US Federal Reserve (Fed) raised interest rates during 1999, initiating the year at 4.75% and entering 2000 at 5.5%, the opposite of what the market expects for the upcoming months.

Another difference comes from a tightening policy that prevailed throughout 1999. The Fed balance sheet contracted to $5.38 trillion by early 2000 from $8.66 trillion the year prior. Today, the script is reversed: the Fed is unlikely to shrink its balance sheet for the next 12 months, especially with signs of softening in the labor market, offering speculative momentum and an extended runway.

US Federal Reserve total assets, USD. Source: TradingView / CointelegraphTudor Jones says a speculative frenzy is distant, expects more gainsTudor expects a “massive rally,” “much more potentially explosive than 1999,” but argues that markets are presently far from a “speculative frenzy.” Tudor added that “it will take more retail buying” and “real money” before a “blow off” top. Tudor Jones is not predicting an immediate downturn, and stock market valuation metrics support this thesis.

S&P 500 forward price-to-earnings ratio. Source: Yardeni ResearchAccording to Yardeni Research data, the S&P 500 forward price-to-earnings multiple sits near 23 times, well below the 25 times peak seen in 2000, implying there is still room for multiple expansion under favorable sentiment. 

Tudor expects “speculative exhaustion” to eventually set in, not an abrupt collapse typically associated with bubble bursts. Tudor Jones recommends allocations tilted toward growth stocks, gold, and Bitcoin as a hedge against inflation and fiscal stress. 

Bitcoin’s $2.5 trillion market capitalization remains modest relative to gold’s $26 trillion and the S&P 500 at $57 trillion. Thus, even if Bitcoin absorbs less than 3% of the $7.37 trillion sitting in the money market, a $200 billion inflow could meaningfully move the price direction. 

This article is for general information purposes and is not intended to be and should not be taken as legal or investment advice. The views, thoughts, and opinions expressed here are the author’s alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

The Bitcoin price has shattered previous records by surging past $126,000, marking a new all-time high this Monday. This milestone has been attributed to the cyclical phenomenon known as “Uptober,” a term coined by analysts to describe October’s historical trend of strong price performance during Halving years.

Bitcoin Price Surge Linked To ‘Safe-Haven Demand’
The rise in Bitcoin and broader crypto prices coincided with the US government shutdown that commenced on October 1. This has fueled greater demand for assets perceived as safe havens, as investors seek stability amidst growing political uncertainty in the United States. 

Further contributing to the Bitcoin price surge, recent data from Bloomberg highlights that investors have injected approximately $3.2 billion into a group of 12 US Bitcoin exchange-traded funds (ETFs) in the past week alone. 

Yet, analysts assert that the Bitcoin options market is increasingly influencing the cryptocurrency’s price movements, reflecting a potential shift in market behavior toward the leading cryptocurrency.

Could $150,000 Be Next?
Rachael Lucas, an analyst at BTC Markets, notes that option traders are eyeing resistance levels at $135,000, with the possibility of reaching $150,000 if current momentum continues. 

The options market currently displays a bullish sentiment, with over 60% of open interest concentrated in call options, signaling strong investor confidence. However, Lucas also raised concerns about the potential for liquidation cascades should momentum falter.

According to Bloomberg’s analysis, the Bitcoin price has averaged gains of approximately 22.5% over the past decade during Uptober rallies. If BTC follows similar patterns, it could reach a new high of $146,000 by the end of the month. 

The daily chart shows BTC’s price uptrend. Source: BTCUSDT on TradingView.com
As of press time, the Bitcoin price has slightly retraced back toward approximately $125,850, recording gains of 100% year-to-date. 

Featured image from DALL-E, chart from Tradingview.com 

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Ronaldo is a seasoned crypto enthusiast with over four years of experience in the field. He is passionate about exploring the vast and dynamic world of decentralized finance (DeFi) and its practical applications for achieving economic sovereignty. Ronaldo is constantly seeking to expand his knowledge and expertise in the DeFi space, as he believes it holds tremendous potential for transforming the traditional financial landscape.

In the relentless quest for groundbreaking cancer therapies, innovative drug trials are reshaping treatment landscapes and redefining patient hope. Arcus Biosciences Inc. (NYSE:RCUS) on Monday announced new monotherapy data for casdatifan in late-line metastatic clear cell renal cell carcinoma (ccRCC).

ARC-20 is a Phase 1/1b dose-escalation and expansion study with four monotherapy cohorts (n=121): 50mg twice daily (BID), 50mg once daily (QD), 100mg QD (tablet), and 150mg QD.

New Casdatifan Data

In the 100mg tablet cohort, Phase 3 dose and formulation, casdatifan showed a 35% confirmed overall response rate (ORR), with two additional responses pending confirmation, and median progression-free survival (mPFS) had not been reached, even with a median follow-up of one year.

Pooled data for the 121 patients treated with casdatifan monotherapy, casdatifan showed a confirmed ORR of 31% and a median PFS of 12.2 months, which is meaningfully longer than published data from studies with the only marketed HIF-2a inhibitor and for TKIs alone in a similar patient population and setting, the company said on Monday.

At the time of data cut-off (Aug. 15, 2025), most patients (81%) had experienced disease control, with either a partial response or stable disease. Seventy-four percent (28 of the 38) of confirmed responders across all four cohorts remained on treatment.

No unexpected safety signals were observed, and casdatifan had an acceptable and manageable safety profile across all doses.

Across all four cohorts, one patient discontinued treatment due to anemia, and four (3%) discontinued due to hypoxia. Summaries of the efficacy and safety data are below.

Expansion into Immunology and Inflammation (I&I): Potential new drug candidates include:

MRGPRX2 small-molecule inhibitor, a potential treatment for atopic dermatitis and chronic spontaneous urticaria.
TNF-a (TNFR1) small-molecule inhibitor, a potential treatment for rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (such as ulcerative colitis).
CCR6 small-molecule inhibitor, a potential treatment for psoriasis
CD89 monoclonal antibody, a potential treatment for RA.
CD40L small-molecule inhibitor, a potential treatment for multiple sclerosis and systemic lupus erythematosus.
RCUS Price Action: Arcus Biosciences shares were up 7.87% at $14.40 at the time of publication on Monday. The stock is trading within its 52-week range of $6.50 to $18.98, according to Benzinga Pro data.

Read Next:

ASML Ends Ties With Former France FM Bruno Le Maire, Stock Hits 52-Week High
Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Investors have until November 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Allegation Details:

According to the complaint, during the class period, defendants failed to disclose that: (i) the MOLBREEVI Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; and (iv) the delay in MOLBREEVI's regulatory approval increased the likelihood that the Company would need to raise additional capital.Plaintiff alleges that on May 27, 2025, Savara issued a press release "announc[ing] that the Company received [a refusal to file ("RTF")] letter from the FDA for the [MOLBREEVI BLA] as a therapy to treat patients with [aPap]." Specifically, Savara revealed that "[u]pon preliminary review, the FDA determined that the [MOLBREEVI BLA] was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC)." On this news, Savara's stock price fell $0.90 per share, or 31.69%, to close at $1.94 per share on May 27, 2025.
Next Steps:

If you purchased or otherwise acquired Savara shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Key Takeaways Vertiv shares jumped 31.5% in a month, beating the Computer and Technology sector's 5.7% gain.
VRT raised 2025 revenue guidance to $9.93-$10.08B, with organic sales growth of 23%%.Recent acquisitions and AI-focused launches strengthen Vertiv's data center infrastructure portfolio.

Vertiv (VRT - Free Report) shares have gained 31.5% in a month, outperforming the broader Zacks Computer and Technology sector’s increase of 5.7%.

Vertiv’s shares have also outperformed its peers, which include Super Micro Computer (SMCI - Free Report) and Hewlett-Packard Enterprise (HPE - Free Report) , both of which are expanding their capabilities to serve hyperscale and enterprise AI data center deployments. Hewlett-Packard and Super Micro Computer shares have gained 3.9% and 29.8%, respectively, in the past month.

The outperformance can be attributed to VRT’s extensive product portfolio, which spans thermal systems, liquid cooling, UPS, switchgear, busbars, and modular solutions, a notable feature.

In the trailing 12 months, organic orders grew approximately 11%, with a book-to-bill of 1.2 times for the second quarter of 2025, indicating a strong prospect. Backlog grew 7% sequentially and 21% year over year to $8.5 billion.

VRT Stock's Performance
Image Source: Zacks Investment Research

VRT Benefits From Strategic AcquisitionsVertiv is a leading provider of thermal and power management solutions for data centers that consume immense amounts of power. The increasing complexity of AI hardware and edge computing further increases the demand for power. Vertiv’s energy-efficient power and cooling solutions play a critical role in this aspect.

Acquisitions have played an important role in further expanding Vertiv’s footprint. In August, Vertiv acquired Waylay NV, a Belgium-based company known for its hyperautomation and generative AI software.

This move aims to improve its AI-driven monitoring and control technologies for power and cooling systems. The acquisition boosts Vertiv’s capacity to provide smart infrastructure solutions that optimize energy use, increase uptime, and enhance operational intelligence in data centers worldwide.

The company also completed its $200 million acquisition of Great Lakes Data Racks & Cabinets, broadening its rack, cabinet, and integrated infrastructure offerings for critical digital infrastructure.

Vertiv Benefits From Expanding PortfolioVertiv’s expanding portfolio has been a major growth driver for its success. In August, Vertiv announced the global launch of Vertiv OneCore. This is a scalable, prefabricated data center solution that combines power, thermal and IT infrastructure into one factory-assembled system.

OneCore is designed to speed up high-density deployments. It simplifies installation, reduces on-site complexity, and supports flexible, energy-efficient setups for AI and enterprise applications.

Vertiv Benefits From Rich Partner BaseVertiv’s rich partner base, which includes Ballard Power Systems, Compass Datacenters, NVIDIA (NVDA - Free Report) , Oklo, Intel, ZincFive, and Tecogen, has been noteworthy.

In June 2025, Vertiv announced its energy-efficient 142KW cooling and power reference architecture for the NVIDIA GB300 NVL72 platform. Vertiv solutions are available as SimReady 3D assets in the NVIDIA Omniverse Blueprint for AI factory design and operations.

VRT Raises 2025 GuidanceVertiv is benefiting from its strong portfolio and rich partner base, which will continue to benefit the company’s top-line growth.

For 2025, revenues are now expected to be between $9.925 billion and $10.075 billion. Organic net sales growth is expected to be between 23% and 25%.

VRT expects 2025 non-GAAP earnings between $3.75 and $3.85 per share.

For third-quarter 2025, revenues are expected to be between $2.510 billion and $2.590 billion. Organic net sales are expected to increase in the 20% to 24% range.

VRT expects third-quarter 2025 non-GAAP earnings between 94 cents and $1.00 per share.

VRT’s Earnings Estimates Revisions Are SteadyThe Zacks Consensus Estimate for third-quarter 2025 earnings is currently pegged at 99 cents per share, which has remained unchanged over the past 30 days. The figure indicates a year-over-year increase of 30.26%.

The Zacks Consensus Estimate for Vertiv’s 2025 revenues is pegged at $9.98 billion, suggesting growth of 24.55% year over year.

The Zacks Consensus Estimate for 2025 earnings is currently pegged at $3.83 per share, which has increased by a penny over the past 30 days. This indicates a 34.39% increase from the 2024 reported figure.

Vertiv Stock is Trading at a PremiumVertiv is currently overvalued, as suggested by a Value Score of D.

In terms of the trailing 12-month Price/Book, Vertiv is currently trading at 19.57X, compared with the broader Computer and Technology sector’s 11.25X,  Super Micro Computer’s and Hewlett Packard’s 4.90X and 1.32X, respectively.

VRT Valuation
Image Source: Zacks Investment Research

ConclusionVertiv is benefiting from its strong portfolio and rich partner base, which are driving order growth. These factors justify the company’s premium valuation.

Vertiv stock currently carries a Zacks Rank #2 (Buy) and has a Growth Score of A, a favorable combination that offers a strong investment opportunity, per the Zacks Proprietary methodology. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into definitive agreements with several accredited and/or institutional investors for the sale of 678,125 shares of the Company’s common stock at an offering price of $1.60 per share in a registered direct offering. The Company’s stock closed at $1.50 per share on October 3, 2025. In a concurrent private placement offering, the Company also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 508,594 shares of the Company’s common stock (the “Unregistered Warrants”), representing 75% warrant coverage. The Unregistered Warrants will have an exercise price of $2.75 per share and will be exercisable commencing six months from the date of issuance until the five year anniversary of the date of issuance. The gross proceeds of the offering will be $1.085 million, before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected to take place on or about October 8, 2025.

The Company intends to use the net proceeds of the offering in connection with its clinical trials with respect to its lead cell therapy candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem® Program, the development of its commercial biocosmeceuticals platform and for general corporate purposes and working capital.

“We appreciate the support of this high-conviction group of existing and new healthcare specialist investors, anchored by our largest institutional shareholder,” said Lance Alstodt, Chief Executive Officer of BioRestorative. “Members of our executive team also participated. With this investment, together with our existing cash, we believe that we are well-positioned to continue executing on our strategic goals.”

Alere Financial Partners (a division of Cova Capital Partners, LLC) acted as the exclusive placement agent for the offering.

The shares in the offering are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-269631) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on February 14, 2023. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement, relating to the offering, which will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying prospectus may also be obtained, when available, from Cova Capital Partners, LLC, 6851 Jericho Turnpike, Suite 205, Syosset, New York 11791, or by telephone at (866) 772-8081.

The Unregistered Warrants are being offered in the concurrent private placement offering pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), provided for in Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: [email protected]

Quantum Computing (QUBT) is up over 3,000% over the last year even after its sell-off Monday. George Tsilis points out the company's issue of $750 million in private placement as a culprit.

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations. Investors who have lost money in their MoonLake Immunotherapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mltx.

What is this all about?

Shares of MoonLake Immunotherapeutics fell more than 85% in pre-market trading on September 29 after the company disclosed disappointing Phase 3 VELA results. One trial failed to meet its primary endpoint, and the other showed only modest gains versus placebo. MoonLake previously touted the results of its Phase 2 MIRA trial. Analysts now contend the Phase 3 data falls short of that benchmark and is lagging competing drugs, raising doubts about the drug’s commercial viability. Block & Leviton is investigating MoonLake's public statements about its drug trials.

Who is eligible?

Anyone who purchased MoonLake Immunotherapeutics common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.

Whistleblower?

If you have non-public information about MoonLake Immunotherapeutics, you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.

Why should you contact Block & Leviton?

Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected]